Selected research
Industry Research
Urotropin for Injection Industry Research Report 2026
Market perspective
The global Urotropin for Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Urotropin for Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Urotropin for Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Urotropin for Injection include Yantai Dongcheng North Pharmaceutical, Teva, Shanghai Tianwei Biopharmaceutical Co., Ltd., Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd., Qingdao Kangyuan Pharmaceutical, Ningbo Human Health Pharmaceutical Group, Ningbo Human Health Pharmaceutical, Merck and Maanshan Fengyuan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Urotropin for Injection market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Urotropin for Injection Market by Company
Yantai Dongcheng North Pharmaceutical
Teva
Shanghai Tianwei Biopharmaceutical Co., Ltd.
Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
Qingdao Kangyuan Pharmaceutical
Ningbo Human Health Pharmaceutical Group
Ningbo Human Health Pharmaceutical
Merck
Maanshan Fengyuan Pharmaceutical
Livzon Group
Ferring GmbH
Livzon
IBSA Group
GenSci
Gedeon Richter
Urotropin for Injection Segment by Type
75 Unit
150 Unit
Urotropin for Injection Segment by Application
Hospital
Clinic
Urotropin for Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urotropin for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urotropin for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urotropin for Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Urotropin for Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Urotropin for Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Urotropin for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 75 Unit
- 150 Unit
Applications
- Hospital
- Clinic
Companies covered
- Yantai Dongcheng North Pharmaceutical
- Teva
- Shanghai Tianwei Biopharmaceutical Co., Ltd.
- Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
- Qingdao Kangyuan Pharmaceutical
- Ningbo Human Health Pharmaceutical Group
- Ningbo Human Health Pharmaceutical
- Merck
- Maanshan Fengyuan Pharmaceutical
- Livzon Group
- Ferring GmbH
- Livzon
- IBSA Group
- GenSci
- Gedeon Richter
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Urotropin for Injection Market Size (2021-2032)
- 2.2.2 Global Urotropin for Injection Sales (2021-2032)
- 2.2.3 Global Urotropin for Injection Market Average Price (2021-2032)
- 2.3 Urotropin for Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 75 Unit
- 2.3.3 150 Unit
- 2.4 Urotropin for Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Urotropin for Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Urotropin for Injection Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Urotropin for Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Urotropin for Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Urotropin for Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Urotropin for Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Urotropin for Injection, Product Type & Application
- 3.8 Global Manufacturers of Urotropin for Injection, Established Date
- 3.9 Global Urotropin for Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yantai Dongcheng North Pharmaceutical
- 4.1.1 Yantai Dongcheng North Pharmaceutical Company Information
- 4.1.2 Yantai Dongcheng North Pharmaceutical Business Overview
- 4.1.3 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Product Portfolio
- 4.1.5 Yantai Dongcheng North Pharmaceutical Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Urotropin for Injection Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Shanghai Tianwei Biopharmaceutical Co., Ltd.
- 4.3.1 Shanghai Tianwei Biopharmaceutical Co., Ltd. Company Information
- 4.3.2 Shanghai Tianwei Biopharmaceutical Co., Ltd. Business Overview
- 4.3.3 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio
- 4.3.5 Shanghai Tianwei Biopharmaceutical Co., Ltd. Recent Developments
- 4.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
- 4.4.1 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Company Information
- 4.4.2 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Business Overview
- 4.4.3 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio
- 4.4.5 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Recent Developments
- 4.5 Qingdao Kangyuan Pharmaceutical
- 4.5.1 Qingdao Kangyuan Pharmaceutical Company Information
- 4.5.2 Qingdao Kangyuan Pharmaceutical Business Overview
- 4.5.3 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Product Portfolio
- 4.5.5 Qingdao Kangyuan Pharmaceutical Recent Developments
- 4.6 Ningbo Human Health Pharmaceutical Group
- 4.6.1 Ningbo Human Health Pharmaceutical Group Company Information
- 4.6.2 Ningbo Human Health Pharmaceutical Group Business Overview
- 4.6.3 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Product Portfolio
- 4.6.5 Ningbo Human Health Pharmaceutical Group Recent Developments
- 4.7 Ningbo Human Health Pharmaceutical
- 4.7.1 Ningbo Human Health Pharmaceutical Company Information
- 4.7.2 Ningbo Human Health Pharmaceutical Business Overview
- 4.7.3 Ningbo Human Health Pharmaceutical Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Ningbo Human Health Pharmaceutical Urotropin for Injection Product Portfolio
- 4.7.5 Ningbo Human Health Pharmaceutical Recent Developments
- 4.8 Merck
- 4.8.1 Merck Company Information
- 4.8.2 Merck Business Overview
- 4.8.3 Merck Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Merck Urotropin for Injection Product Portfolio
- 4.8.5 Merck Recent Developments
- 4.9 Maanshan Fengyuan Pharmaceutical
- 4.9.1 Maanshan Fengyuan Pharmaceutical Company Information
- 4.9.2 Maanshan Fengyuan Pharmaceutical Business Overview
- 4.9.3 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Product Portfolio
- 4.9.5 Maanshan Fengyuan Pharmaceutical Recent Developments
- 4.10 Livzon Group
- 4.10.1 Livzon Group Company Information
- 4.10.2 Livzon Group Business Overview
- 4.10.3 Livzon Group Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Livzon Group Urotropin for Injection Product Portfolio
- 4.10.5 Livzon Group Recent Developments
- 4.11 Ferring GmbH
- 4.11.1 Ferring GmbH Company Information
- 4.11.2 Ferring GmbH Business Overview
- 4.11.3 Ferring GmbH Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Ferring GmbH Urotropin for Injection Product Portfolio
- 4.11.5 Ferring GmbH Recent Developments
- 4.12 Livzon
- 4.12.1 Livzon Company Information
- 4.12.2 Livzon Business Overview
- 4.12.3 Livzon Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Livzon Urotropin for Injection Product Portfolio
- 4.12.5 Livzon Recent Developments
- 4.13 IBSA Group
- 4.13.1 IBSA Group Company Information
- 4.13.2 IBSA Group Business Overview
- 4.13.3 IBSA Group Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 IBSA Group Urotropin for Injection Product Portfolio
- 4.13.5 IBSA Group Recent Developments
- 4.14 GenSci
- 4.14.1 GenSci Company Information
- 4.14.2 GenSci Business Overview
- 4.14.3 GenSci Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 GenSci Urotropin for Injection Product Portfolio
- 4.14.5 GenSci Recent Developments
- 4.15 Gedeon Richter
- 4.15.1 Gedeon Richter Company Information
- 4.15.2 Gedeon Richter Business Overview
- 4.15.3 Gedeon Richter Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Gedeon Richter Urotropin for Injection Product Portfolio
- 4.15.5 Gedeon Richter Recent Developments
5 Global Urotropin for Injection Market Scenario by Region
- 5.1 Global Urotropin for Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Urotropin for Injection Sales by Region: 2021-2032
- 5.2.1 Global Urotropin for Injection Sales by Region: 2021-2026
- 5.2.2 Global Urotropin for Injection Sales by Region: 2027-2032
- 5.3 Global Urotropin for Injection Revenue by Region: 2021-2032
- 5.3.1 Global Urotropin for Injection Revenue by Region: 2021-2026
- 5.3.2 Global Urotropin for Injection Revenue by Region: 2027-2032
- 5.4 North America Urotropin for Injection Market Facts & Figures by Country
- 5.4.1 North America Urotropin for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Urotropin for Injection Sales by Country (2021-2032)
- 5.4.3 North America Urotropin for Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Urotropin for Injection Market Facts & Figures by Country
- 5.5.1 Europe Urotropin for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Urotropin for Injection Sales by Country (2021-2032)
- 5.5.3 Europe Urotropin for Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Urotropin for Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Urotropin for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Urotropin for Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Urotropin for Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Urotropin for Injection Market Facts & Figures by Country
- 5.7.1 South America Urotropin for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Urotropin for Injection Sales by Country (2021-2032)
- 5.7.3 South America Urotropin for Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Urotropin for Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Urotropin for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Urotropin for Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Urotropin for Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Urotropin for Injection Sales by Type (2021-2032)
- 6.1.1 Global Urotropin for Injection Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Urotropin for Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Urotropin for Injection Revenue by Type (2021-2032)
- 6.2.1 Global Urotropin for Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Urotropin for Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Urotropin for Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Urotropin for Injection Sales by Application (2021-2032)
- 7.1.1 Global Urotropin for Injection Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Urotropin for Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Urotropin for Injection Revenue by Application (2021-2032)
- 7.2.1 Global Urotropin for Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Urotropin for Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Urotropin for Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Urotropin for Injection Value Chain Analysis
- 8.1.1 Urotropin for Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Urotropin for Injection Production Mode & Process
- 8.2 Urotropin for Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Urotropin for Injection Distributors
- 8.2.3 Urotropin for Injection Customers
9 Global Urotropin for Injection Analyzing Market Dynamics
- 9.1 Urotropin for Injection Industry Trends
- 9.2 Urotropin for Injection Industry Drivers
- 9.3 Urotropin for Injection Industry Opportunities and Challenges
- 9.4 Urotropin for Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst